Moncas (Montelukast)

Montelukast, the active ingredient in Moncas, is a leukotriene receptor antagonist presented as a tablet for oral use. It is used to manage asthma and allergic rhinitis in adults and children.

GNH USA supplies Moncas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to control chronic respiratory conditions. - Asthma: improves long‑term control and reduces exacerbations. - Allergic rhinitis: relieves nasal congestion, sneezing and itching. - Exercise‑induced bronchoconstriction: prevents airway narrowing during physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache - Abdominal pain - Cough - Dyspepsia - Fatigue - Nausea

Serious or Rare Side Effects: - Angioedema or severe allergic reactions - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Anaphylaxis - Hepatic injury - Neuropsychiatric events such as mood changes or suicidal thoughts - Eosinophilic granulomatosis with polyangiitis

When prescribing Montelukast, consider the following safety measures. - Neuropsychiatric monitoring: watch for mood changes, depression, or suicidal thoughts. - Hepatic caution: use carefully in patients with liver impairment. - Not for acute asthma attacks: should not replace rescue inhalers. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Drug interaction awareness: review concomitant medications that affect CYP enzymes. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Montelukast may interact with other medicines that influence its metabolism or therapeutic effect.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, phenobarbital, carbamazepine) which can reduce exposure. - Concurrent use with other leukotriene modifiers may increase risk of adverse effects.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) may increase plasma levels. - Fluconazole or erythromycin: potential modest increase in exposure. - Warfarin: monitor INR as Montelukast may affect anticoagulation. - Oral contraceptives: may slightly reduce Montelukast efficacy.